Subscribe to RSS - BioScrip


BioScrip’s earnings decline


DENVER – BioScrip reported net revenues of $182.6 million for the fourth quarter of 2017, down from $198.7 million in the third quarter.

Short takes: BioScrip, Rotech


Denver-based BioScrip can now dispense and administer HEMLIBRA, a treatment for routine prophylaxis approved by the U.S. Food and Drug Administration.

BioScrip bolsters management team


DENVER – BioScrip has added two new execs to its management team: Harriet Booker as senior vice president and COO, and Danny Claycomb as senior vice president of revenue cycle management.

‘Disruptors’ put a dent in BioScrip’s earnings


DENVER – Company officials at BioScrip blamed a second straight quarter of net revenue declines on several “disrupters,” both expected and unexpected.

Short takes: BioScrip, Paragon Ventures, Stratice Healthcare, Invacare


BioScrip is now dispensing and administering Radicava, the first treatment option for ALS approved by the U.S. Food and Drug Administration in more than 20 years…Paragon Ventures, a healthcare M&A firm, has launched

BioScrip revenues are down, but core product mix is up


DENVER – BioScrip’s net revenues decreased 6.2% in the second quarter of 2017, but CEO Dan Greenleaf said in an earnings call the company was hitting targets.

BioScrip’s losses rack up in Q2


DENVER – BioScrip reported net revenues of $218.1 million for the second quarter of 2017 compared to $232.4 million for the same period a year ago. Net loss was $29.2 million vs. $8.2 million.

In brief: Judge deals setback to Arriva Medical, BioScrip reports earnings


CORAL SPRINGS, Fla. – Arriva Medical on April 25 lost an appeal seeking to reinstate its Medicare billing privileges, according to news reports.

BioScrip earnings ‘in line’ with expectations


DENVER – BioScrip reported net revenues of $217.8 million for the first quarter of 2017, reflecting a core revenue mix of 72% compared to 60% during the same quarter in 2016. Net loss was $19 million and adjusted EBITD was 5.2 million.

'Clear mission' says Greenleaf


With one full financial quarter under his belt, BioScrip President and CEO Dan Greenleaf says the company is reinvigorated and on track to right itself.